Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Primary Objective
\- To assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific anti-HLA antibodies and in those with active disease
Secondary Objectives
* To determine the long term fate of the haplo transplant and the cord blood transplant in this setting.
* To describe the incidence and severity of acute and chronic GVHD.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed or refractory acute leukemia (myeloid or lymphoid)
Acute leukemia in first remission at high-risk for recurrence
Chronic myelogenous leukemia in accelerated phase or blast-crisis
Chronic myelogenous leukemia in chronic phase
Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
Chronic lymphocytic leukemia, relapsed or with poor prognostic features
Multiple myeloma
Myelodysplastic syndrome
Chronic myeloproliferative disease
Hemoglobinopathies
Aplastic anemia
You may not be if
Zubrod performance status \> 2
Life expectancy is severely limited by concomitant illness
Patients with severely decreased LVEF or impaired pulmonary function tests
Estimated Creatinine Clearance \<50 ml/min
Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal
Evidence of chronic active hepatitis or cirrhosis
HIV-positive
Patient is pregnant
Patient or guardian not able to sign informed consent
